On Friday, January 13th, the CARE™ Faculty specialists representing the fields of gastroenterology, hematology, oncology, respirology and rheumatology met to consider the integration of biosimilars into the Canadian healthcare system.
With biosimilars being relatively new to the Canadian landscape, there are also a number of questions/considerations on extrapolating data, interchangeability, immunogenicity, and systemic challenges (tracking and monitoring) that require attention.
Recognizing both the potential impact on the Canadian healthcare system and the importance of involving stakeholders, CARE™ faculty invited 16 speakers representing Canadian researchers, clinicians, Health Canada, public and private funding agencies, health economists, hospital pharmacists, nurses, advocacy groups, ethicists and legal experts to share perspectives, concerns, wants and needs. Over 100 people were in attendance, representing the aforementioned stakeholders, along with various levels of government, pharmaceutical companies and industry associations, listened in while speakers and assembled faculty discussed biosimilars from multiple perspectives.
Marriott Downtown at CF Toronto Eaton Centre,
Bay Street, Toronto, ON, Canada
Dr. John Marshall (CARE™ Gastroenterology Faculty, McMaster University)
Dr. John Kuruvilla (CARE™ Hematology Faculty, Princess Margaret Cancer Centre)
Dr. Hartmut Grasemann (CARE™ Respirology Faculty, The Hospital for Sick Children)